Skip to main content

Table 2 Differentiation status CMV-CTL isolated after enrichment by three week expansion in the presence of CMVpp65495–503 peptide

From: Assessment of the effector function of CMV-specific CTLs isolated using MHC-multimers from granulocyte-colony stimulating factor mobilized peripheral blood

  G-CSF mobilized Non-mobilized
  TN TCM TEM TEMRA TN TCM TEM TEMRA
Before expansion 0.35 % ± 0.07 0.05 % ± 0.07 75.10 % ± 9.90 24.50 % ± 9.76 0.50 % ± 0.87 0.13 % ± 0.23 67.33 % ± 32.66 32.07 % ± 32.98
Expanded PBMCs 0.05 % ± 0.07 0.15 % ± 0.07 99.55 % ± 0.07 0.20 % ± 0.14 0.17 % ± 0.29 0.03 % ± 0.06 90.87 % ± 11.52 8.97 % ± 11.23
Positive fraction 0.00 % ± 0.00 0.10 % ± 0.14 99.70 % ± 0.14 0.15 % ± 0.07 0.00 % ± 0.00 0.10 % ± 0.10 96.70 % ± 3.32 3.20 % ± 3.39
  1. TN, TCM, TEM and TEMRA subpopulations were determined for G-CSF mobilized and non-mobilized samples in the original PBMC sample (n = 3), PBMCs after 21 day in vitro expansion (n = 3), and positive fraction of CMV-CTL isolation after culture (n = 3). Percentages were obtained from the CD3 + CD8 + ST+ cell subpopulation